GenVec Inc  

(Public, NASDAQ:GNVC)   Watch this stock  
Find more results for GNVC
-0.04 (-1.36%)
Real-time:   12:20PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.85 - 2.95
52 week 1.61 - 4.67
Open 2.95
Vol / Avg. 33,204.00/115,340.00
Mkt cap 50.25M
P/E     -
Div/yield     -
EPS -0.16
Shares 17.27M
Beta 1.67
Inst. own 37%
May 11, 2015
Q1 2015 GenVec Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 24, 2015
Q4 2014 GenVec Inc Earnings Call - Webcast
Mar 24, 2015
Q4 2014 GenVec Inc Earnings Release
Mar 9, 2015
GenVec Inc at ROTH Conference
Feb 9, 2015
GenVec Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 48.63% -41.63%
Operating margin 48.40% -42.00%
EBITD margin - -38.35%
Return on average assets 46.87% -22.00%
Return on average equity 55.64% -28.09%
Employees 11 -
CDP Score - -


910 Clopper Rd Ste 220n
United States - Map
+1-240-6320740 (Phone)
+1-240-6320735 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


GenVec, Inc. (GenVec) is a biopharmaceutical company, engaged in the creation of therapeutics and vaccines. The Company works with companies and organizations, such as Novartis, Merial and the United States Government to support a range of product programs that address the prevention and treatment of a number of human and animal health concerns. The Company�s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company�s products are developed with its adenovector technology, which uses modified adenoviruses to deliver genes to target cells. It started preclinical programs to develop vaccine candidates for the prevention of RSV and HSV.

Officers and directors

Wayne T. Hockmeyer Ph.D. Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Douglas J. Swirsky President, Chief Executive Officer, Corporate Secretary, Director
Age: 45
Bio & Compensation  - Reuters
James V. Lambert Chief Financial Officer, Chief Accounting Officer, Senior Director, Controller, Treasurer
Age: 50
Bio & Compensation  - Reuters
Bryan T. Butman Ph.D. Senior Vice President - Development
Age: 62
Bio & Compensation  - Reuters
Douglas E. Brough Ph.D. Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Stefan D. Loren Ph.D. Director
Age: 51
Bio & Compensation  - Reuters
Quinterol J. Mallette M.D. Director
Age: 41
Bio & Compensation  - Reuters
William N. Kelley M.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Marc R. Schneebaum Independent Director
Age: 61
Bio & Compensation  - Reuters